Presentation

Our research combines AI and glycobiology to revolutionize disease detection and treatment by identifying glycan (complex carbohydrate) biomarkers and developing targeted therapeutic proteins that recognize disease-specific glycans. The project tackles the critical challenge of delayed disease diagnosis, which often leads to poor patient outcomes and limited treatment options. The goal is to enable earlier and more accurate disease detection while simultaneously providing precise, personalized treatment strategies through glycan-targeting proteins. So far, we have successfully validated these AI methods for identifying glycan biomarkers and designing therapeutic proteins in laboratory settings. However, to advance toward market-ready solutions, we need to strengthen our expertise in regulatory affairs and seek industry partnerships to implement our innovations in clinical applications.